Long-term effectiveness and safety of high dose chemotherapy followed by autologous stem cell transplantation in daily practice in patients with diffuse large B-cell lymphoma
Journal of Clinical and Experimental Hematopathology · 2023
DOI: 10.3960/jslrt.23001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical and Experimental Hematopathology, 2023. Verfasst von Takahiro Haeno und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Rheumatology, Kindai University Hospital, Osaka, Japan. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
We retrospectively evaluated long-term outcomes of high dose chemotherapy followed by autologous stem cell transplant (HDC/ASCT) in patients with diffuse large B-cell lymphoma (DLBCL). Between 2004 and 2020, 46 DLBCL patients received HDC/ASCT in our institution, including 12 patients (26.1%), who received as an upfront setting (UFS). At a median follow-up time of 69 months (range, 2-169 months), the 5-year progression-free survival (PFS) rates were 82.5% (95%CI, 46.1-95.3%) in the UFS, and 57.8% (95%CI, 38.1-73.2%) in the relapsed or refractory (R/R) patients (n=34), respectively. The 5-year PFS rates were 62.3% (95%CI, 34.0-81.3%) in primary resistant (n=13) or early relapsing (within 1 year from the initial diagnosis) patients (n=4), and 53.3% (95%CI, 25.9-74.6%) in those relapsing >1 year after the initial diagnosis (n=17), with no statistically significant difference (p=0.498). In R/R patients, multivariate analysis showed that the remission status before HDC/ASCT was an independent poor prognostic factor for progression-free survival (hazard ratio [HR], 17.0; 95%CI, 3.35-86.6; p=0.000630) and high-risk category in the international prognostic index for OS (HR, 9.39; 95%CI, 1.71-51.6; p=0.0100). The incidence of non-relapse mortality by 5 years, and 10 years were 12.2%, and 15.2%, respectively. Eleven patients (23.9%) developed second malignancies, which was the most frequent late complication after HDC/ASCT, with 5-year, and 10-year cumulative incidence of 16.9%, 22.5%, respectively. In conclusion, HDC/ASCT is effective for chemo-sensitive R/R DLBCL regardless of the timing and lines of therapy. However, careful observation is required, considering the long-term complications such as secondary malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology and Rheumatology, Kindai University Hospital, Osaka, Japan.
Zitieren
APA
Haeno, T., Rai, S., Miyake, Y., Inoue, M., Fujimoto, K., Fujii, A., Iwata, Y., Minamoto, S., Taniguchi, T., Kakutani, H., Inoue, H., Kumode, T., Serizawa, K., Taniguchi, Y., Hirase, C., Morita, Y., Tanaka, H., Tatsumi, Y., Ashida, T., & Matsumura, I. (2023). Long-term effectiveness and safety of high dose chemotherapy followed by autologous stem cell transplantation in daily practice in patients with diffuse large B-cell lymphoma. Journal of Clinical and Experimental Hematopathology. https://doi.org/10.3960/jslrt.23001
Vancouver
Haeno T, Rai S, Miyake Y, Inoue M, Fujimoto K, Fujii A, et al. Long-term effectiveness and safety of high dose chemotherapy followed by autologous stem cell transplantation in daily practice in patients with diffuse large B-cell lymphoma. Journal of Clinical and Experimental Hematopathology. 2023. doi:10.3960/jslrt.23001
BibTeX
@article{Haeno2023,
author = {Haeno, Takahiro and Rai, Shinya and Miyake, Yoshiaki and Inoue, Maiko and Fujimoto, Ko and Fujii, Aki and Iwata, Yoshio and Minamoto, Shuji and Taniguchi, Takahide and Kakutani, Hiroaki and Inoue, Hiroaki and Kumode, Takahiro and Serizawa, Kentaro and Taniguchi, Yasuhiro and Hirase, Chikara and Morita, Yasuyoshi and Tanaka, Hirokazu and Tatsumi, Yoichi and Ashida, Takashi and Matsumura, Itaru},
title = {Long-term effectiveness and safety of high dose chemotherapy followed by autologous stem cell transplantation in daily practice in patients with diffuse large B-cell lymphoma},
journal = {Journal of Clinical and Experimental Hematopathology},
year = {2023},
doi = {10.3960/jslrt.23001}
}
EUVIMED